Review article: the histological assessment of disease activity in ulcerative colitis
Open Access
- 24 August 2015
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 42 (8) , 957-967
Abstract
Backgound In patients with ulcerative colitis (UC), mucosal healing has emerged as a major therapeutic goal, and is usually assessed endoscopically. Histological healing does not correlate very well with endoscopic mucosal healing in UC and persistent histological inflammation might be a better predictor of future clinical relapse than the endoscopic appearance alone. Aim To define how histological assessment of disease activity should be best done in UC. Methods Electronic (PubMed/Embase) and manual search. Results At least 18 histological indices to assess disease activity in UC have been described, though none are fully validated. However, histological assessment is increasingly used as a secondary endpoint in clinical trials in UC. After reviewing and discussing existing histological scoring systems for UC activity, we describe features of histological response and define three grades of activity: (i) histological healing – complete resolution of abnormalities; (ii) quiescent disease, – lack of mucosal neutrophils but chronic inflammation may remain; (iii) active disease – presence of neutrophils plus possible epithelial damage. It is recommended that two biopsies are taken from each colonic segment which should include always biopsy of the rectum and the most affected segments. There is to date no agreed preferable scoring system but the Geboes Index is the best validated (kappa for interobserver variation 0.59–0.70). Conclusion Histological assessment of disease activity in UC is increasingly used, but needs to be carefully defined.Keywords
This publication has 61 references indexed in Scilit:
- Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-upGut, 2015
- Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiativeJournal of Crohn's and Colitis, 2014
- Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBDJournal of Crohn's and Colitis, 2013
- Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel diseaseJournal of Crohn's and Colitis, 2011
- Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left‐sided ulcerative colitisAlimentary Pharmacology & Therapeutics, 2010
- Histologic Inflammation Is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort StudyGastroenterology, 2007
- Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitisGastroenterology, 2004
- Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging studyGastroenterology, 1998
- Microscopic activity in ulcerative colitis: what does it mean?Gut, 1991
- Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various dietsDigestive Diseases and Sciences, 1966